AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04857034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06053411
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg capsule
Trial: NCT05521282
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
Trial: NCT06107686
Drug: YL202 should be intravenously infused
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Trial: NCT06430411
Drug: Androgen deprivation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Trial: NCT05020119
Drug: Neoantigen-expanded cell therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of personalized neoantigen-expanded T (CIK) cells
Trial: NCT04641975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/ Oral Suspension
Trial: NCT05685407
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
Trial: NCT06440746
Drug: Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
Trial: NCT06440746
Drug: SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
Trial: NCT05304962
Drug: RGT-419B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT05313256
Drug: Lidocaine epinephrine buffered with sodium bicarbonate
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
Trial: NCT05313256
Drug: Lidocaine epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
Trial: NCT04344860
Drug: Recombinant Von Willebrand factor
RxNorm normalized name: VON WILLEBRAND FACTOR,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
Trial: NCT04213274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Trial: NCT04593329
Drug: TIRADENTES ASSOCIATION
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiradentes association tablet
Trial: NCT05734807
Drug: Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive NrtIs therapy for 24 weeks.
Trial: NCT05734807
Drug: HH-003, NrtIs and PEG-IFN-α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
Trial: NCT05984992
Drug: SRN-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
Trial: NCT05984992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride(Normal saline)
Trial: NCT04560309
Drug: L-alanyl-L-glutamine dipeptide
RxNorm normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
Trial: NCT04560309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
Trial: NCT05814939
Drug: VC005 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 groups repeat administration for 12 weeks
Trial: NCT05979818
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Trial: NCT05814939
Drug: VC005 Tablets Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 placebo groups repeat administration for 12 weeks
Trial: NCT05675293
Drug: ORAL ANTIBIOTIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Antibiotic
Trial: NCT06081465
Drug: VG290131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug and matching placebo will be administered orally.
Trial: NCT05284747
Drug: Routine Lipid Management
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
Trial: NCT05249348
Drug: PC14586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
Trial: NCT06048705
Drug: GSK3901961
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3901961 was administered.
Trial: NCT06048705
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.
Trial: NCT06465602
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
Trial: NCT06465602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
Trial: NCT06125327
Drug: SC1011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
Trial: NCT06125327
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
Trial: NCT05240976
Drug: NMDAE plus AIFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
Trial: NCT05240976
Drug: NMDAE plus Placebo Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer plus placebo as a comparator
Trial: NCT05280314
Drug: IO102-IO103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
Trial: NCT04654052
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-intervention
Trial: NCT05788328
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin as oral tablet
Trial: NCT05527314
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
Trial: NCT05527314
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Trial: NCT05624957
Drug: Lidocaine epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
Trial: NCT04632381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose injection, USP
Trial: NCT05092503
Drug: JINZHEN Granules for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JINZHEN granules will be dissolved in drinking water and administered orally.
Trial: NCT05092503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules will be dissolved in drinking water and administered orally.
Trial: NCT06532344
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05257213
Drug: Heparin solution
RxNorm normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 ml saline solution containing 5000 IU heparin.
Trial: NCT05257213
Drug: Anti-adhesion barrier gel
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
Trial: NCT04990310
Drug: [14C]-CORT113176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
Trial: NCT06223009
Drug: cNP8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
Trial: NCT02544815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills
Trial: NCT05909709
Drug: Alocyte medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used.
Trial: NCT05068830
Drug: ExPlas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.
Trial: NCT05261490
Drug: Pegylated Liposomal Doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
Trial: NCT06327256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching BI 3000202
Trial: NCT05234580
Drug: PA9159 nasal spray solution, 10 μg once daily for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Trial: NCT05234580
Drug: PA9159 nasal spray solution, 20 μg once daily for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Trial: NCT05234580
Drug: PA9159 nasal spray solution, 40 μg once daily for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Trial: NCT05234580
Drug: Placebo nasal spray solution without PA9159, once daily for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Trial: NCT05860868
Drug: 2 cycles induction chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Trial: NCT05860868
Drug: 3 cycles induction chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Trial: NCT06082817
Drug: Oral Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg oral testosterone undecanoate daily
Trial: NCT06432452
Drug: Endothelin Receptor Antagonist
RxNorm normalized name: Endothelin receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules twice daily
Trial: NCT04849000
Drug: SHR-1209 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1209 Placebo
Trial: NCT06163807
Drug: Antiasthmatic
RxNorm normalized name: ANTIASTHMA,ANTILEUKOTRIENES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: real-life
Trial: NCT05013086
Drug: 1.48 GBq of 177Lu-AB-3PRGD2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: accepted intravenous injection of 177Lu-AB-3PRGD2
Trial: NCT06496412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take placebo capsules.
Trial: NCT00005931
Drug: SU5416
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06685978
Drug: Xiang Ju Ru Pi Ning capsule Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
Trial: NCT06695741
Drug: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
Trial: NCT06403267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml 0.9% normal Saline
Trial: NCT05810649
Drug: Freshly manufactured 35 kDa hyaluronan fragment
RxNorm normalized name: PALMITOYL FRAGMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
Trial: NCT06517511
Drug: R-CHOP Protocol
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Trial: NCT05889741
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5cc of Normal Saline one time into the stellate ganglion.
Trial: NCT06496971
Drug: Microbubble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
Trial: NCT00002101
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05338450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent to experimental arm
Trial: NCT06548620
Drug: RD06-04 cell infusion
RxNorm normalized name: SET,INFUSION ANIMAS #240-04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR T Cells
Trial: NCT04693715
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNS60 injection solution
Trial: NCT04693715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection solution
Trial: NCT04829214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection
Trial: NCT05838885
Drug: YPEG-rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
Trial: NCT05838885
Drug: YPEG-rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
Trial: NCT04991597
Drug: Lidocaine Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
Trial: NCT04991597
Drug: Lidocaine Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
Trial: NCT04869124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
Trial: NCT06158477
Drug: JYP0035 Experimental Drug Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intervention
Trial: NCT05587998
Drug: AZD4041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral doses of AZD4041 as stated in arm description.
Trial: NCT06527937
Drug: Epinephrine Injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
Trial: NCT06121284
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
Trial: NCT05879432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution
Trial: NCT04669392
Drug: 70% Ethanol Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time.